Online citations, reference lists, and bibliographies.

Long-term Proton Pump Inhibitor Therapy And Risk Of Hip Fracture.

Yu-Xiao Yang, J D Lewis, Sol Epstein, David C. Metz
Published 2006 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
CONTEXT Proton pump inhibitors (PPIs) may interfere with calcium absorption through induction of hypochlorhydria but they also may reduce bone resorption through inhibition of osteoclastic vacuolar proton pumps. OBJECTIVE To determine the association between PPI therapy and risk of hip fracture. DESIGN, SETTING, AND PATIENTS A nested case-control study was conducted using the General Practice Research Database (1987-2003), which contains information on patients in the United Kingdom. The study cohort consisted of users of PPI therapy and nonusers of acid suppression drugs who were older than 50 years. Cases included all patients with an incident hip fracture. Controls were selected using incidence density sampling, matched for sex, index date, year of birth, and both calendar period and duration of up-to-standard follow-up before the index date. For comparison purposes, a similar nested case-control analysis for histamine 2 receptor antagonists was performed. MAIN OUTCOME MEASURE The risk of hip fractures associated with PPI use. RESULTS There were 13,556 hip fracture cases and 135,386 controls. The adjusted odds ratio (AOR) for hip fracture associated with more than 1 year of PPI therapy was 1.44 (95% confidence interval [CI], 1.30-1.59). The risk of hip fracture was significantly increased among patients prescribed long-term high-dose PPIs (AOR, 2.65; 95% CI, 1.80-3.90; P<.001). The strength of the association increased with increasing duration of PPI therapy (AOR for 1 year, 1.22 [95% CI, 1.15-1.30]; 2 years, 1.41 [95% CI, 1.28-1.56]; 3 years, 1.54 [95% CI, 1.37-1.73]; and 4 years, 1.59 [95% CI, 1.39-1.80]; P<.001 for all comparisons). CONCLUSION Long-term PPI therapy, particularly at high doses, is associated with an increased risk of hip fracture.
This paper references
10.1021/ja049607w
Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors.
Jai Moo Shin (2004)
10.1093/oxfordjournals.epirev.a017956
Epidemiology of hip fractures.
Robert Graham Cumming (1997)
10.1080/07315724.1995.10718522
Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans.
C Serfaty-Lacrosniere (1995)
10.1007/s00223-006-0021-7
Proton Pump Inhibitors, Histamine H2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture
Peter Vestergaard (2006)
10.2174/1381612023393369
Selective inhibition of osteoclast vacuolar H(+)-ATPase.
Carlo Farina (2002)
10.1001/archinte.1991.00400100100017
A model of lifetime osteoporosis impact.
Elizabeth A. Chrischilles (1991)
10.1007/BF01116615
Modularity of osteoclast behaviour and “mode-specific” inhibition of osteoclast function
M. Zaidi (1990)
The General Practice Research Database: quality of morbidity data.
John Hollowell (1997)
10.1046/j.1365-2036.2003.01798.x
Is there any association between myocardial infarction, gastro-oesophageal reflux disease and acid-suppressing drugs?
Sten R. Johansson (2003)
10.3177/jnsv.44.869
Effect of L-lactic acid on the absorption of calcium in gastrectomized rats.
Osamu Chonan (1998)
10.1136/jech.44.3.241
Incidence of fractures in a geographically defined population.
Liam J. Donaldson (1990)
10.1136/bmj.300.6732.1092
The Read clinical classification.
Joan M. Chisholm (1990)
10.1097/00006254-200109000-00017
Use of Statins and Risk of Fractures
Tjeerd-Pieter van Staa (2001)
10.1128/cmr.10.4.720
Helicobacter pylori.
Bruce E. Dunn (1997)
10.1007/BF02556841
Omeprazole, a specific inhibitor of H+−K+-ATPase, inhibits bone resorptionin vitro
Juha Tuukkanen (2007)
10.1002/1099-1557(200009/10)9:5<359::AID-PDS507>3.0.CO;2-E
The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results.
Tjeerd-Pieter van Staa (2000)
10.1002/pds.1115
The relationship between time since registration and measured incidence rates in the General Practice Research Database.
J D Lewis (2005)
10.7326/0003-4819-139-6-200309160-00010
Thiazide Diuretics and the Risk for Hip Fracture
Mariette W C J Schoofs (2003)
10.1007/BF01352010
Effect of omeprazole, an inhibitor of H+, K+-ATPase, on bone resorption in humans
Kazutoshi Mizunashi (2005)
10.1016/s0899-9007(97)83011-0
Calcium and osteoporosis.
B. E. Christopher Nordin (1988)
10.1046/j.1532-5415.2002.50455.x
Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study.
Cynthia L. Leibson (2002)
10.1172/JCI111254
An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium.
George W. Bo-Linn (1984)
10.1136/gut.26.3.252
Regulation of vitamin D and calcium metabolism after gastrectomy.
Lisbeth Nilas (1985)
[Involutional osteoporosis].
Hajime Orimo (1991)
10.1056/NEJM198708273170903
Gastrointestinal absorption of calcium from milk and calcium salts.
M S Sheikh (1987)
A model of lifetime osteoporosis
EA Chrischilles (1991)
10.3177/jnsv.44.473
Effect of L-lactic acid on calcium absorption in rats fed omeprazole.
Osamu Chonan (1998)
10.2307/2530744
Biased selection of controls for case-control analyses of cohort studies.
Jay H. Lubin (1984)
10.1056/NEJM198507113130202
Calcium absorption and achlorhydria.
Robert Roy Recker (1985)
10.1359/jbmr.2001.16.3.581
Use of oral corticosteroids and risk of fractures.
Tjeerd Pieter van Staa (2000)
10.1002/jbmr.5650070514
Risk of fractures in patients with pernicious anemia.
J B Goerss (1992)
OXMIS Problem Codes for Primary Medical Care
J. Perry (1978)
10.1002/art.1780360601
The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.
David T Felson (1993)
10.1016/j.amjmed.2005.02.007
Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial.
Mary Beth O'Connell (2005)
10.2165/00003088-199223060-00006
Pharmacokinetic Study of Omeprazole in Elderly Healthy Volunteers
S. Landahl (1992)
10.1007/s001980200089
Calcium Supplement and Bone Medication Use in a US Medicare Health Maintenance Organization
B. Dawson-Hughes (2002)
10.7326/0003-4819-66-5-917
The absorption of calcium carbonate.
Peter Ivanovich (1967)
10.1016/S0016-5085(00)83955-4
Who is using chronic acid-suppression therapy and why?
Brian Jacobson (2000)
10.1001/jama.291.20.2457
Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles.
An-Wen Chan (2004)



This paper is referenced by
10.1007/s40141-019-00220-z
Polypharmacy and Rational Prescribing: Changing the Culture of Medicine One Patient at a Time
Sook Kyung Yoon (2019)
10.11005/jbm.2018.25.3.141
Proton-pump Inhibitor Use and Fracture Risk: An Updated Systematic Review and Meta-analysis
Yousef Nassar (2018)
10.1186/1471-2474-14-304
Urban versus rural differences in the occurrence of hip fractures in Japan’s Kyoto prefecture during 2008–2010: a comparison of femoral neck and trochanteric fractures
Motoyuki Horii (2013)
10.1007/s00198-016-3510-1
Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis
C.-H. Chen (2016)
Osteoporosis: An Endocrinologist’s Perspective
M T Mcdermott (2010)
10.1177/014556130908800501
Restrictions on Business Relationships with Industries, and Their Unintended Adverse Consequences
Robert Thayer Sataloff (2009)
DDDT_A_193559 1347..1356
Hung-Hsien Chiang (2019)
10.1590/S1984-82502010000400003
Elderly and drugs: risks and necessity of rational use
André Oliveira Baldoni (2010)
10.1007/s00391-012-0374-7
Osteoporosis and polypharmacy
M Gosch (2012)
Calcium and Vitamin D in the prevention and treatment of osteoporosis: Shedding light on new developments
Ian B. Hollis (2007)
10.1053/j.gastro.2009.11.014
Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.
Laura E Targownik (2010)
10.1038/bonekey.2013.230
Vitamin D endocrine system and the intestine.
Sylvia Christakos (2014)
Pharmacokinetic interaction between fluvoxamine and lansoprazole in healthy volunteers.
Maria Adriana Neag (2016)
10.1007/s12325-017-0532-9
A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors
Li-Yuan Yu (2017)
10.1155/2008/284165
Hip fracture and proton pump inhibitor therapy: position statement.
Paul Moayyedi (2008)
10.1007/s11938-017-0115-5
Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors
Felice Schnoll-Sussman (2017)
10.4021/gr379w
Proton Pump Inhibitors Interfere With Zinc Absorption and Zinc Body Stores
Christopher P. Farrell (2011)
10.1038/s41467-017-00309-w
Micromotor-enabled active drug delivery for in vivo treatment of stomach infection
Berta Esteban-Fernández de Ávila (2017)
10.4082/kjfm.2015.36.5.239
Helicobacter pylori: A Possible Risk Factor for Bone Health
Yun Hee Chung (2015)
10.1038/ajg.2017.24
Complex Relationship Between Proton Pump Inhibitor Use and Bone Health
Ting Zhu (2017)
10.1007/s12603-015-0512-1
Association of Proton Pump Inhibitor Use with Recurrent Falls and Risk of Fractures in Older Women: A Study of Medication Use in Older Fallers.
Heinrich Wolfgang Thaler (2016)
10.1016/j.jpeds.2011.08.067
Over-prescription of acid-suppressing medications in infants: how it came about, why it's wrong, and what to do about it.
Eric Hassall (2012)
10.1053/j.gastro.2008.01.010
The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
Laura E Targownik (2008)
10.3164/jcbn.12-15
Strategies for peptic ulcer healing after 1 week proton pump inhibitor-based triple Helicobacter pylori eradication therapy in Japanese patients: differences of gastric ulcers and duodenal ulcers
Toshihisa Takeuchi (2012)
10.2147/TCRM.S3552
The use of calcium and vitamin D in the management of osteoporosis
John A Sunyecz (2008)
Clinical epidemiological studies of drug safety and disease risk factors using large primary care databases
Yana Vinogradova (2017)
10.1097/MD.0000000000014422
Proton pump inhibitor use and risk of dementia
Min Li (2019)
Impact de l'hospitalisation sur la polymédication des personnes âgées et évaluation à six mois après la sortie auprès des médecins généralistes : cas particulier des inhibiteurs de la pompe à protons
Julie Nava Maire (2015)
10.1111/jvim.15337
ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats
Stanley L Marks (2018)
10.1097/MEG.0000000000001198
Adverse outcomes of long-term use of proton pump inhibitors: a systematic review and meta-analysis
Md Mohaimenul Islam (2018)
Osteoporosis in Depression: Which Patients Are at Risk? Psychotropics Increase Fracture Risk; Depression Compounds Poor Bone Health
Charles Hébert (2010)
10.1177/1526924816669725
A Comparison of Histamine Receptor Antagonists Versus Proton Pump Inhibitor Gastrointestinal Ulcer Prophylaxis in Kidney Transplant Recipients
Ginger E Rouse (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar